Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Omnicell, Inc.
  6. News
  7. Summary
    OMCL   US68213N1090


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Omnicell : STOMPP Study Demonstrates Multimed Packaging Improves Medication Adherence

06/12/2018 | 08:13am EDT

STOMPP Study Demonstrates Multimed Packaging Improves Medication Adherence

June 12, 2018


Omnicell, Inc. (NASDAQ: OMCL) announced the results of the STOMPP (Study to Measure the Impact of Pharmacists and Pharmacy Services on Medication Non-Adherence) clinical study. This randomized controlled trial compares the use of adherence medication packaging and medication therapy management (MTM) services to the use of traditional pill bottles. The results indicate a clear improvement in clinical outcomes and adherence rates when using multimed blister card packaging and MTM services.

In the STOMPP study, patients were randomly assigned to one of four groups based on whether they received their medications dispensed in vials (pill bottles) vs. multimed blister packaging, and whether or not they received pharmacist-provided MTM. While improvements with use of multimed packaging and MTM services were proven individually and in combination, study participants who received multimed blister cards had the most marked change in adherence scores when compared to pill bottle groups, achieving adherence scores greater than 45 percent above baseline.

Further evidence of the benefits of multimed packaging as demonstrated by the STOMPP study is highlighted below:

  • Patients assigned to the multimed packaging groups reached medication adherence rates of 80 percent almost immediately upon enrollment.

  • These patients achieved 90 percent adherence rates by the end of the one-year study period.

  • By contrast, patients assigned to the pill bottle-only group reached a maximum of 56 percent adherence.

To combat the $290 billion problem of medication nonadherence, innovative pharmacies must employ a variety of tools designed to change patient behavior. Omnicell is committed to helping resolve this crisis through a comprehensive portfolio of solutions that are part of the company's integrated medication management platform. These include the market-leading Time My Meds® medication synchronization software, Pharmacy Line Interactive Voice Response, SureMed® Multimed Blister Cards, Guided Packing, and automated packaging systems, including the VBM 200F and the M5000. This unique set of solutions is enabled through Omnicell's Patient Management Access Portal (PMAP), web-based software that centralizes all patient engagement.

'As a nation, we need to do a better job at managing complex patients, as 80 million patients are expected to have more than one chronic condition by 2030,' said Dr. Sharrel Pinto, B.S. Pharm, D.M.M., M.S., Ph.D., division head and associate professor of Health Outcomes and Socioeconomic Sciences of the University of Toledo College of Pharmacy and Pharmaceutical Sciences and Director of the Pharmaceutical Care and Outcomes Research (PCOR) laboratory. 'STOMPP reinforces the adherence pharmacy model, and affirms the value of the pharmacist as a key member of the care team in not only improving the experience and health of these patients, but also reducing the overall costs associated with their care. Using the arsenal of tools now available to this industry, including medication synchronization technology and blister packaging, pharmacists can help patients significantly impact their health.'


The primary endpoint of STOMPP, measured at one year, was to determine if the use of adherence packaging and/or medication therapy management in the hybrid pharmacy practice model has an impact on medication adherence. The study followed patients within a regional integrated delivery network (IDN) who had been diagnosed with type 2 diabetes, hypertension, and/or hyperlipidemia for one year to assess clinical outcome measures, quality of life, and cost and utilization data.

At baseline, most patients were on approximately 10 prescription medications, had a body mass index of more than 30, and uncontrolled diabetes with HbA1c greater than seven percent. Patients were randomized into four groups where they received pill bottle medications, blister packaging, pill bottles and MTM, or blister packaging and MTM.

Other study findings include:

  • Patients who received multimed packaging reached their blood pressure goals sooner than those who did not use multimed packaging;

  • Patients who only received their medications in pill vials with no other pharmacy-based services had the poorest health outcomes, incurred higher costs, and utilized more healthcare resources than patients in other groups;

  • Patients who received multimed packaging and MTM had the lowest average HbA1c values (used to measure average blood sugar levels) at the end of the year when compared to the other groups.

'Our pharmacy partners know the impact they can have on patient care when they're able to offer additional resources to their patients. The STOMPP study formalizes what we have known as an industry for years, and allows these providers to advocate for a greater involvement in patient care teams moving forward,' said Rob Seim, president of Global Automation and Medication Adherence, Omnicell. 'We're proud that our packaging has such a marked impact on medication adherence, and we applaud the frontline pharmacists for continuing to look for new innovations and solutions that will allow them to better care for their patients.'

Dr. Pinto served as the study's Principal Investigator and lead researcher. The results were presented at the American Pharmacists Association Annual Meeting and published in Innovations in Pharmacy.

The STOMPP study was funded through an unrestricted grant from Omnicell.


i. Annals of Internal Medicine. 'Interventions to Improve Adherence to Self-administered Medications for Chronic Diseases in the United States: A Systematic Review,' last accessed March 6, 2018. http://annals.org/aim/fullarticle/1357338/interventions-improve-adherence-self-administered-medications-chronic-diseases-united-states

ii Centers for Medicare and Medicaid Services, 'Chronic care management: Is the $50 billion market more hype than reality?' last accessed March 6, 2018. http://www.healthcareitnews.com/news/chronic-care-management-50-billion-market-more-hype-reality


Omnicell Inc. published this content on 12 June 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 12 June 2018 12:12:08 UTC

ę Publicnow 2018
All news about OMNICELL, INC.
06/09OMNICELLá : JPMorgan Starts Omnicell at Neutral With $146 Price Target
05/28OMNICELL, INCá : Submission of Matters to a Vote of Security Holders (form 8-K)
05/24OMNICELLá : BTIG Starts Omnicell at Buy With $165 Price Target
05/18INSIDER TRENDS : 90-Day Insider Buying Trend at Omnicell Eased Back with Disposi..
04/30OMNICELLá : Berenberg Bank Adjusts Omnicell PT to $168 From $152, Maintains Buy ..
04/30OMNICELLá : to Provide Medication Management Solution to Scripps Health
04/27OMNICELLá : EnlivenHealth Partners With Twilio to Accelerate Launch of Transform..
04/07OMNICELLá : Aultman Health Foundation to Enhance Medication Management with Omni..
04/01OMNICELLá : to Release First Quarter 2021 Financial Results on April 29, 2021
More news
Financials (USD)
Sales 2021 1 101 M - -
Net income 2021 82,3 M - -
Net cash 2021 123 M - -
P/E ratio 2021 75,2x
Yield 2021 -
Capitalization 6 206 M 6 206 M -
EV / Sales 2021 5,52x
EV / Sales 2022 4,74x
Nbr of Employees 2 970
Free-Float 80,2%
Duration : Period :
Omnicell, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMNICELL, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 10
Average target price 153,50 $
Last Close Price 143,68 $
Spread / Highest target 18,3%
Spread / Average Target 6,83%
Spread / Lowest Target -23,4%
EPS Revisions
Managers and Directors
Randall A. Lipps Chairman, President & Chief Executive Officer
Peter J. Kuipers Chief Financial Officer & Executive Vice President
Giri Chodavarapu Chief Information Officer
Bill Wingfield Vice President-North America Service & Operations
Dan S. Johnston Secretary, Chief Legal & Administrative Officer
Sector and Competitors
1st jan.Capitalization (M$)
OMNICELL, INC.19.71%6 206
VEEVA SYSTEMS INC.12.65%46 900
SECTRA AB (PUBL)-12.34%2 869